Local recurrence of malignant tumor of urinary bladder (disorder)
BL-13
Year Started: 2019
A randomised phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Genomic datasets | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Psychological data | > 6 months |
Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of cervix (disorder)
CRAIN
Year Started: 2022
A phase 1b TiTE-CRM dose escalation clinical trial of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Not-started
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Genomic datasets | > 6 months |
Pathology records | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | RT | Affected | 75% -99% | ||
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
DNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Tissue specimen | RT | Affected | 75% -99% | ||
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
DNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Diffuse non-Hodgkin's lymphoma (disorder)
Pola-R-ICE-polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) vs R-ICE in patients with primary refractory or relapsed DLBCL
Year Started: 2022
tissue specimen, serum, plasma,
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Not-started
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | > 6 months |
Genomic datasets | > 6 months |
Imaging data | > 6 months |
National registries | > 6 months |
Treatment records | > 6 months |
Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Diffuse large B-cell lymphoma (nodal/systemic with skin involvement) (disorder)
ACCEPT
Year Started: 2017
A Phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patient with Diffuse Large B-cell Lymphoma
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | > 6 months |
Followup records | > 6 months |
Freezer temperature logs | > 6 months |
Genomic datasets | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |